{
    "Trade/Device Name(s)": [
        "FreeStyle Libre 2 Flash Glucose Monitoring System",
        "FreeStyle Libre 2 Sensor",
        "FreeStyle Libre 2 MediRx Sensor"
    ],
    "Submitter Information": "Abbott Diabetes Care, Inc.",
    "510(k) Number": "K211102",
    "Predicate Device Reference 510(k) Number(s)": [
        "K193371"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QLG",
        "NBW"
    ],
    "Summary Letter Date": "April 12, 2021",
    "Summary Letter Received Date": "April 13, 2021",
    "Submission Date": "April 12, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1355",
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "POCT"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "FreeStyle Libre 2 Reader"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical sensor",
        "Amperometric measurement",
        "Glucose oxidase enzyme reaction"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Reader"
    ],
    "Document Summary": "FDA 510(k) summary for FreeStyle Libre 2 Flash Glucose Monitoring System with real-time alarms, intended for management of diabetes and compatible with FreeStyle Libre 2 Sensor (14-day) and FreeStyle Libre 2 MediRx Sensor (10-day)",
    "Indications for Use Summary": "Continuous glucose monitoring system with real-time alarms for diabetes management in persons age 4 and older, intended to replace blood glucose testing for diabetes treatment decisions, aids detection of hyperglycemia/hypoglycemia and communicates with digitally connected devices",
    "fda_folder": "Clinical Chemistry"
}